Slow growth forecast for female contraceptives market

The contraceptives market across the seven major markets (7MM: the USA, France, Germany, Italy, Spain, UK and Japan) is forecast to slightly increase at a compound annual growth rate (CAGR) of 0.5% from $7.8 billion in 2022 to $8.2 billion in 2032.

Pharma analytics company GlobalData’s latest report “ Female Contraceptives in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2032,” reveals that oral contraceptives dominate the contraceptives market, and this trend is not projected to dramatically change over the next 10 years.

GlobalData expects limited pipeline drugs to enter the market, with one late-stage pipeline drug to launch during the forecast period in the US, Spain, and UK, while two marketed drugs are expected to launch in Japan. Together, these late-stage pipeline products are expected to add around $53.1 million in sales to the contraceptives market in 2032.